Treatment of Grade 3 (Moderately Symptomatic) Immune Checkpoint Inhibitor-Induced Hypophysitis

Clinical Scenario

Grade 3 — Moderately Symptomatic
This protocol addresses hypophysitis that arises as a consequence of immune checkpoint inhibitor (ICI) therapy. At grade 3 severity, the patient is experiencing moderately symptomatic disease requiring a structured clinical response, including a decision about whether to continue, delay, or re-initiate immunotherapy.

Specific Situation

Immune checkpoint inhibitor-induced hypophysitis (ICIHy) at grade 3 represents a moderate-severity immune-related adverse event. Management at this grade requires timely action regarding ongoing ICI therapy and careful evaluation of the patient's hormonal status. Re-initiation of ICI after the acute episode must be weighed against clinical response.

Treatment Approach (Partial)

The approach involves delaying immune checkpoint inhibitor therapy while initiating appropriate hormonal support. The specific agents used, their sequencing, and the criteria for ICI re-initiation are detailed in the full structured regimen.

Full regimen, decision criteria, and monitoring parameters available via the link below →

Instant Access to Structured Evidence-Based Regimens

References

For grade 3 (moderately symptomatic) ICIHy, ICI therapy must be delayed and re-initiation of ICI must be considered based on clinical response to hormonal replacement/glucocorticoid treatment.

DOI: 10.1016/j.beem.2019.101371

View source ↗